Sponsored by PERQUE Integrative Health
It has long been known that dental and orthopedic devices and materials may have a negative impact on certain patients. In this interview, integrative medical expert and immunologist Russell Jaffe, MD, PhD, CCN, explains how to accurately identify immunocompatibility and risk for patients undergoing dental and/or orthopedic procedures. Jaffe explains how reactivity testing can be used to create more effective and less dangerous treatment plans for sensitive patients.
About the Expert
Russell Jaffe, MD, PhD, CCN, CEO and Chairman of PERQUE Integrative Health, is one of the pioneers of integrative and regenerative medicine. Since inventing the world’s first single-step amplified (ELISA) procedure in 1984, a process for measuring and monitoring all delayed allergies, Jaffe has continually sought new ways to help speed the transition from our current healthcare system’s symptom-reactive model to a more functionally integrated, effective and compassionate system. PIH is the outcome of years of Jaffe’s scientific research. It brings to market three decades of rethinking safer, more effective, novel and proprietary dietary supplements, supplement delivery systems, diagnostic testing, and validation studies.
About the Sponsor
PERQUE Integrative Health (PIH) is dedicated to speeding the transition from sickness care to healthful caring. Delivering novel, personalized health solutions, PIH gives healthcare practitioners and patients the tools to achieve sustained optimal wellness. Combining the best in functional, evidence-based testing with premium professional supplements, and healthful lifestyle guides, PIH solutions deliver successful outcomes in even the toughest cases. Visit
ELISAACT.com and
PERQUE.com for more.